This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis | MicrobiomeTrials
← Back to trials NCT04372108
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis Recruiting OBSERVATIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2021-06-24Est. Completion: 2029-08-31
Enrollment target: 1,536 participantsLocations BAMC, Houston, Texas, United States Other microbiome trials you might be interested in Inflammatory Bowel Diseases (IBD) Crohn Disease Colitis, Ulcerative
Difficult-to-treat inflammatory bowel disease (DTT-IBD) represents a heterogeneous group of patients with treatment-refr…
Multiple Locations Est. completion Oct 31, 2032
Inflammatory Bowel Disease
This study evaluates oral Lactobacillus reuteri as an adjunct therapy for 2 months. Endoscopic assessments will be perfo…
Suqian, China Completed Mar 30, 2026
Phase 4
Recruiting
This is an open-label, single-arm, phase 4 study to assess the safety and efficacy of mirikizumab in approximately 60 pa…
Miami, United States Est. completion Sep 1, 2027